BroadOak Capital Partners

What BroadOak Capital Partners does

BroadOak Capital Partners, founded in 2006 by Bill Snider and Lars Hanan, is a privately held boutique financial institution exclusively focused on the life sciences industry. Operating from offices in Bethesda (DC metro), San Francisco, and Raleigh (Research Triangle), the firm provides two integrated services through distinct regulated entities: BroadOak Asset Management (SEC-registered investment adviser) delivers direct growth capital to commercial-stage life sciences companies, while BroadOak Partners (FINRA/SIPC broker-dealer) provides M&A advisory, capital raising, and strategic advisory services. The firm invests across three subsectors — life sciences tools ($130B market), diagnostics ($50B), and biopharma services ($100B) — and often serves as the first institutional investor in portfolio companies, leveraging flexible deal structures with no minimum investment threshold to serve companies underserved by traditional financial institutions.

The firm has built a diversified capital platform comprising seven investment funds and six special purpose vehicles, with over $300M in total capital deployed across 75+ portfolio companies and 50+ advised M&A transactions since inception. Recent platform expansion includes the BioTools Venture Fund (launched October 2022 with DeciBio Consulting, focused on pre-commercialization biotools and cell/gene therapy), the BroadOak Income Fund (a private credit vehicle, final closing March 2025), Fund VI (initial closing June 2025), and a $200M+ permanent capital base added in October 2025 alongside Research Corporation Technologies. Revenue is generated through investment management fees, transaction-based advisory fees, and carried interest from investment vehicles; pricing is negotiated per transaction and not publicly disclosed. Distribution is relationship-driven — direct outreach, industry events (annual BroadOak Investor Days, BioTools Innovator, Phacilitate Advanced Therapies Week), and an entrepreneur inquiry form — supplemented by three US offices and a European BD presence (UK-based VP Pete Corish).

The firm is owned by its principals, with leadership including five Partners (Bill Snider, D. Kyle Wilson, Tim Johnson, Lars Hanan, Matt McFarland), three Operating Partners with PhD scientific backgrounds (Anup Parikh, Aaron Goldman, Trent Carrier), three Managing Directors, and a team of ~17 across investment, advisory, and operations. Recent strategic activity includes the $40M debt refinancing of Harvard Bioscience (December 2025) with a board seat for Bill Snider, the launch of Codis as a global CDMO (October 2025), advisory on the Enzo Biochem take-private and Scientific Industries Genie divestiture, and continued co-investment activity in portfolio companies such as Codis, Pluristyx, PAK BioSolutions, and PBS Biotech.

Name

BroadOak Capital Partners

Legal name

BroadOak Partners, LLC

Website

https://broadoak.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

BroadOak Capital Partners is a privately held, life-sciences-focused boutique financial institution founded in 2006, providing growth capital (via BroadOak Asset Management) and M&A/capital-raising advisory (via BroadOak Partners) to commercial-stage companies in life sciences tools, diagnostics, and biopharma services.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Banking

NAICS

Portfolio Management and Investment Advice (52394), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Corporate Finance & Capital Advisory (BPAHADAB)

akta.pro secondary industry

Multi-Sector / Generalist Growth Equity (FSANACAO)

Keywords

• Life sciences investment
• Investment banking advisory
• Growth capital
• M&A advisory
• Venture capital funds

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Management (BroadOak Asset Management): BroadOak provides direct growth capital investments to life sciences companies. Returns come from equity appreciation, dividends, and exits through M&A or other liquidity events. The firm manages multiple funds including Fund VI, BroadOak Income Fund, and special purpose vehicles, with over $200M in permanent capital added in 2025.
2. Investment Banking Advisory (BroadOak Partners): BroadOak Partners provides M&A advisory, sell-side and buy-side advisory, equity/debt/mezzanine capital raising, leveraged transactions, valuations, and strategic financial advisory services. Revenue is generated through transaction fees and success-based compensation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

BroadOak Capital Partners is a boutique financial institution that provides growth capital and investment banking advisory services to life sciences companies. Through BroadOak Asset Management, it invests directly in commercial-stage life sciences tools, diagnostics, and biopharma services companies; through BroadOak Partners (FINRA/SIPC broker-dealer), it provides M&A advisory, capital raising, and strategic financial advisory services to the same sector.

Product overview

BroadOak Capital Partners is a life sciences focused boutique financial institution operating two core divisions: BroadOak Asset Management provides direct growth capital investments to commercial-stage life sciences companies, while BroadOak Partners offers investment banking advisory services including M&A, capital markets, and strategic advisory. The firm supports companies across the life sciences tools, diagnostics, and biopharma services sectors. BroadOak complements its core offerings with the BioTools Innovator accelerator program, the BioTools Venture Fund (early-stage growth capital in partnership with DeciBio), the BroadOak Income Fund (private credit for mature companies), and Fund VI (growth capital fund family). Since 2006, the firm has invested in more than 70 companies and advised on over 50 successful M&A transactions.

Differentiator

Problem solved

Functional benefit

Products and services

• BroadOak Asset Management (Growth Capital Investing)
• BroadOak Partners (Investment Banking Advisory)
• BioTools Venture Fund
• BroadOak Income Fund
• BroadOak Fund VI
• BioTools Innovator Accelerator Program

Quantifiable outcome

• 120+ life sciences companies partnered with over 15 years
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor and core.

• Guggenheim SecuritiesminorImplementation/ SI/ Consulting Partner · 17 December 2025Guggenheim Securities served as lead financial advisor to Harvard Bioscience in connection with the $40 million debt refinancing transaction with BroadOak.
• DeciBio ConsultingcoreStrategic or Co-development Partner · 1 October 2022BroadOak partnered with DeciBio Consulting to launch the BioTools Venture Fund in October 2022. DeciBio provides strategy consulting and market intelligence serving clients across the precision medicine ecosystem. Together, they provide early-stage growth capital and mentorship to promising young companies in the biotools space with a focus on cell and gene therapy.
• BioTools InnovatorcoreStrategic or Co-development Partner · 1 January 2020BroadOak is a founding sponsor of BioTools Innovator, the world's premier nonprofit accelerator and competition for life science tools and diagnostic companies. The program provides early-stage companies with educational materials, networking opportunities, exposure to key stakeholders, and funding and mentorship. BroadOak has been a proud sponsor since the program began in 2020.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Market position

Competitive moat5 records

Customer concentration

• LinkedInlinkedin.com/company/broadoak-capital-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BroadOak Capital Partners